×

Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

  • US 9,526,730 B2
  • Filed: 10/30/2015
  • Issued: 12/27/2016
  • Est. Priority Date: 05/14/2012
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating nephrotic syndrome, wherein the nephrotic syndrome is minimal change disease (MCD), membranous nephropathy (MN) and/or focal segmental glomerulosclerosis (FSGS);

  • or caused by or associated with minimal change disease (MCD), membranous nephropathy (MN) and/or focal segmental glomerulosclerosis (FSGS), the method comprising administering linagliptin to a patient in need thereof, optionally in combination with one or more other active agents.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×